Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × Solutions × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, T-Cell 1 Head and Neck Carcinoma 1 Glioblastoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

Temozolomide 65 Radiotherapy 26 Bevacizumab 23 Carboplatin 12 Radiation 11 pembrolizumab 10 Irinotecan 7 Carmustine 7 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 Nivolumab 5 Everolimus 5 temsirolimus 4 atezolizumab 4 Vorinostat 4 Radiotherapy, Intensity-Modulated 4 Lomustine 4 Aminolevulinic Acid 4 tipifarnib 3 fludarabine 3 Sirolimus 3 Radiotherapy, Conformal 3 Paclitaxel 3 Magnetic Resonance Spectroscopy 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3 Drug Therapy 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03233152 2025-11-21

GlitIpNi

Universitair Ziekenhuis Brussel

Phase 1/2 Active not recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡